
CHBRP

Assembly Bill 907 (2023) Analysis at a Glance

Coverage for PANDAS and PANS as amended on 3/16/2023

Background Context



PANDAS/PANS are terms used to describe a subset of children with symptoms that include a sudden onset of OCD and/or tic disorders cooccurring with a collection of neuropsychiatric symptoms usually following an infection. PANDAS is classified as a subset of PANS, hypothesized by some to be triggered by a response to Strep bacteria.



PANDAS/PANS has been primarily described in children between the ages of 3 and 12; the exact prevalence and age distribution of PANDAS/PANS is unknown. Much remains unknown about PANDAS/PANS. Controversy exists regarding whether PANDAS differs enough from other disorders to warrant a different diagnostic category.

Bill Summary



Assembly Bill (AB) 907 would require DMHC-regulated health plans and **CDI-regulated health policies to** provide coverage for the prophylaxis, diagnosis, and treatment of **PANDAS** and PANS. Covered treatments must include antibiotics, medications and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and IVIG therapy.

Insurance Subject to the Mandate

Medical Effectiveness

The body of research on PANDAS/PANS is small (number of studies and sample

sizes of available studies). CHBRP found:

- Insufficient evidence on the effectiveness of CBT, psychotropics, NSAIDs, corticosteroids, plasma exchange, rituximab, mycophenolate mofetil, and vitamin D in reducing or eliminating the prominent symptoms associated with PANDAS/PANS.
- Inconclusive evidence on the effectiveness of antibiotics and IVIG in reducing or eliminating the prominent symptoms associated with PANDAS/PANS

CDI and DMHC Regulated (Commercial & CalPERS)



Medi-Cal (DMHC Regulated)

Federally Regulated (Medicare beneficiaries, self-insured, etc.)

Cost Impacts



AB 907 would increase total net annual expenditures by \$2,992,000 or 0.002% for enrollees with DMHC-regulated plans and **CDI-regulated policies.**

Benefit Coverage and Utilization



CHBRP estimates 670 enrollees have a PANDAS/PANS diagnosis

At baseline, 100% of enrollees have coverage for diagnostic tests and all treatments except intravenous immunomodulating therapies, therefore there would be no change in utilization.

0% of enrollees have coverage for intravenous immunomodulating therapies at baseline.

Postmandate, an additional 90 enrollees would receive IVIG at least once per year, 22 would receive 3 infusions of rituximab per year, and 0 would receive plasma exchange. Coverage would remain subject to prior authorization.

California Health Benefits Review Program (CHBRP), California Department of Insurance (CDI), California Department of Managed Health Care (DMHC), Cognitive Behavioral Therapy (CBT), Intravenous Immunoglobulin (IVIG), Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Obsessive Compulsive Disorder (OCD), Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS), Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

www.chbrp.org